Breast Cancer: Related News

A study identifies genetic variations that alter the risk of breast cancer in women who have a certain gene mutation.

A New York State law that went into effect this month requires radiologists to inform women if they have dense breasts. Dr. Lee answers questions about the concept of breast density and what women should know.

New, potentially practice-changing research sheds light on the long-term benefits of estrogen-blocking tamoxifen therapy in women with early-stage breast cancer whose disease is estrogen-receptor positive.

A new Memorial Sloan-Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.

Dr. Mehrara talks about the expertise of Memorial Sloan-Kettering plastic surgeons and how patients with breast cancer and head and neck cancer benefit from recent advances in reconstructive surgery.

Dr. Morrow, Chief of Memorial Sloan-Kettering’s Breast Surgical Service, discusses how our patients with breast cancer are cared for by a true team of experts in every aspect of treatment and recovery.

Dr. Morrow is the first surgeon and the first person from Memorial Sloan-Kettering to receive the American Society of Clinical Oncology’s award, which recognizes breast cancer researchers who are also excellent mentors.

Department of Surgery Chair Peter T. Scardino reflects on the expanding role of surgery at an institution devoted to caring for people with cancer.

Memorial Sloan-Kettering medical oncologist Clifford A. Hudis has been elected President of the American Society of Clinical Oncology, the world’s leading professional organization representing more than 30,000 physicians who care for people with cancer.

Memorial Sloan-Kettering Cancer Center researchers have identified a feature in the DNA of breast cancer cells that might indicate the likelihood a woman’s disease will become life threatening.

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) are reporting in the Journal of Clinical Oncology on the development of a new prediction tool that calculates a patient’s individualized risk for recurrence five and ten years after surgery.

There is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study published in the October 14 issue of the Journal of the American Medical Association, a theme issue on surgical care, found that breast-conserving surgery was presented and provided in the majority of patients evaluated.

New research led by investigators at Memorial Sloan-Kettering Cancer Center sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.